Cannabis use, cognition and brain structure in first-episode psychosis

Imagem de Miniatura
Arquivos
art_CUNHA_Cannabis_use_cognition_and_brain_structure_in_first_2013.PDF (277.11 KB)
Citações na Scopus
47
Tipo de produção
article
Data de publicação
2013
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE BV
Autores
SANTOS, Bernardo dos
MURRAY, Robin M.
CRIPPA, Jose Alexandre S.
Citação
SCHIZOPHRENIA RESEARCH, v.147, n.2-3, p.209-215, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Cannabis use is highly prevalent worldwide and it is associated with psychosis, but its effects on brain structure and cognition are still controversial. The aim of this paper is to investigate cognitive functioning and brain structure in patients with their first episode of psychosis who used Cannabis. We examined gray matter and lateral ventricle volumes in 28 patients with first-episode psychosis and a history of Cannabis use, 78 patients without a history of Cannabis use and 80 healthy controls who had not used Cannabis. Cognition was assessed using forward and backwards digit span tests, from the Wechsler Memory Scale-Third Edition (WMS-III) and the Controlled Oral Word Association Test (COWAT). Patients with a history of Cannabis use had less brain abnormalities, characterized by gray matter and lateral ventricle volume preservation, as well as less attentional and executive impairments compared to patients without a history of Cannabis use. Cannabis-using patients who develop psychosis have less neurodevelopmental impairment and better cognitive reserve than other psychotic patients; perhaps reflecting different etiological processes.
Palavras-chave
Cannabis, First-episode psychosis (FEP), Cognition, Magnetic resonance imaging, Substance use
URI
https://observatorio.fm.usp.br/handle/OPI/2116
Referências
  1. American Psychiatric Association (APA), 2000, DIAGN STAT MAN MENT
  2. Ayres AD, 2010, PSYCHIAT RES, V179, P157, DOI 10.1016/j.psychres.2009.11.001
  3. Ayres AM, 2007, SCHIZOPHR RES, V90, P338, DOI 10.1016/j.schres.2006.09.026
  4. Bangalore SS, 2008, SCHIZOPHR RES, V99, P1, DOI 10.1016/j.schres.2007.11.029
  5. BEBBINGTON P, 1995, INT J METHOD PSYCH, V5, P11
  6. Block RI, 2000, NEUROREPORT, V11, P491, DOI 10.1097/00001756-200002280-00013
  7. Bolla KI, 2002, NEUROLOGY, V59, P1337
  8. Braga RJ, 2012, PSYCHIAT RES, V200, P242, DOI 10.1016/j.psychres.2012.05.025
  9. Cahn W, 2004, SCHIZOPHR RES, V67, P305, DOI 10.1016/S0920-9964(03)00003-3
  10. Cousijn J, 2012, NEUROIMAGE, V59, P3845, DOI 10.1016/j.neuroimage.2011.09.046
  11. Cunha PJ, 2010, ADDICT BEHAV, V35, P875, DOI 10.1016/j.addbeh.2010.05.005
  12. De Hert M, 2011, SCHIZOPHR RES, V126, P270, DOI 10.1016/j.schres.2010.07.003
  13. Fontes MA, 2011, J CLIN EXP NEUROPSYC, V33, P523, DOI 10.1080/13803395.2010.535505
  14. Fontes MA, 2011, BRIT J PSYCHIAT, V198, P442, DOI 10.1192/bjp.bp.110.077479
  15. Hester R, 2009, NEUROPSYCHOPHARMACOL, V34, P2450, DOI 10.1038/npp.2009.67
  16. Howieson DB, 2004, NEUROPSYCHOLOGICAL A
  17. Jager G, 2007, EUR NEUROPSYCHOPHARM, V17, P289, DOI 10.1016/j.euroneuro.2006.10.003
  18. Job DE, 2002, NEUROIMAGE, V17, P880, DOI 10.1006/nimg.2002.1180
  19. Joyal CC, 2003, SCHIZOPHR RES, V63, P297, DOI 10.1016/S0920-9964(02)00387-0
  20. KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261
  21. Koskinen J, 2010, SCHIZOPHRENIA BULL, V36, P1115, DOI 10.1093/schbul/sbp031
  22. Lagerberg TV, 2011, EUR ARCH PSY CLIN N, V261, P397, DOI 10.1007/s00406-011-0188-4
  23. Lorenzetti V, 2010, SUBST USE MISUSE, V45, P1787, DOI 10.3109/10826084.2010.482443
  24. Malchow B., 2012, EUR ARCH PSYCHIAT CL
  25. Martin-Santos R, 2010, PSYCHOL MED, V40, P383, DOI 10.1017/S0033291709990729
  26. Matochik JA, 2005, DRUG ALCOHOL DEPEN, V77, P23, DOI 10.1016/j.drugalcdep.2004.06.011
  27. Menezes PR, 2007, BRIT J PSYCHIAT, V191, pS102, DOI 10.1192/bjp.191.51.s102
  28. Minatogawa-Chang TM, 2009, SCHIZOPHR RES, V113, P200, DOI 10.1016/j.schres.2009.06.020
  29. Moore THM, 2007, LANCET, V370, P319, DOI 10.1016/S0140-6736(07)61162-3
  30. Murray RM, 2007, NAT REV NEUROSCI, V8, P885, DOI 10.1038/nrn2253
  31. Perico CD, 2011, BIPOLAR DISORD, V13, P28, DOI 10.1111/j.1399-5618.2011.00896.x
  32. Rais M, 2010, EUR NEUROPSYCHOPHARM, V20, P855, DOI 10.1016/j.euroneuro.2010.08.008
  33. Rapp C, 2012, CURR PHARM DESIGN, V18, P5070
  34. Rodriguez-Sanchez JM, 2010, SCHIZOPHR RES, V124, P142, DOI 10.1016/j.schres.2010.08.017
  35. Rosa PGP, 2010, WORLD J BIOL PSYCHIA, V11, P873, DOI 10.3109/15622975.2010.486042
  36. Schaufelberger M.S., 2007, BRIT J PSYCHIAT S, V51, P117
  37. Schaufelberger MS, 2011, PSYCHOL MED, V41, P1677, DOI 10.1017/S0033291710002163
  38. Schnell T, 2012, SCHIZOPHR RES, V138, P183, DOI 10.1016/j.schres.2012.03.021
  39. Solowij N, 2012, PSYCHOPHARMACOLOGY, V219, P575, DOI 10.1007/s00213-011-2486-y
  40. SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624
  41. Szeszko PR, 2007, BRIT J PSYCHIAT, V190, P230, DOI 10.1192/bjp.bp.106.024521
  42. Trzesniak C, 2012, PSYCHOL MED, V42, P2523, DOI 10.1017/S0033291712000839
  43. Tzilos GK, 2005, AM J ADDICTION, V14, P64, DOI 10.1080/10550490590899862
  44. UNODC United Nations Office on Drugs and Crime, 2011, WORLD DRUG REP 2011
  45. Wechsler D, 1997, WECHSLER MEMORY SCAL
  46. White J, 2012, J EPIDEMIOL COMMUN H, V66, P767, DOI 10.1136/jech-2011-200252
  47. Wobrock T, 2009, EUR ARCH PSY CLIN N, V259, P28, DOI 10.1007/s00406-008-0831-x
  48. Yucel M, 2012, SCHIZOPHRENIA BULL, V38, P316, DOI 10.1093/schbul/sbq079
  49. Yucel M, 2008, ARCH GEN PSYCHIAT, V65, P694, DOI 10.1001/archpsyc.65.6.694

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPR
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/21
Artigos e Materiais de Revistas Científicas - LIM/23
Artigos e Materiais de Revistas Científicas - LIM/39